中文
EN
R&D and Innovation
R&D and Innovation
News Center
R&D System and Platforms
As a pharmaceutical company that starts with research and development and progressively builds an integrated, end-to-end value chain, Viwit has always regarded R&D as the core engine of its sustainable growth. Guided by the strategic principle of “Comprehensive focus on innovation, driven by insight and science”, we continue to build a complete R&D system covering drug discovery, pharmaceutical development (CMC), preclinical research, and clinical research.
The company invests approximately 10% of its annual revenue in R&D and has assembled a highly qualified, dedicated R&D team. This team represents a vital asset that enables us to overcome challenges and explore the frontiers of science.
To translate scientific concepts into reality, we have established integrated, collaborative product development centers in Shanghai, the United States, Tengzhou (Shandong), and Zaozhuang (Shandong). These centers encompass multiple specialized teams, including target discovery, AI-driven drug design, compound screening, biological evaluation, process development, analytical research, formulation development, and clinical research management.
In parallel, we have also built specialized laboratories and production lines for radiopharmaceutical R&D and manufacturing, and have obtained a Class B Radiation Safety Permit. This endows us with full-chain qualifications for the development and production of radiopharmaceuticals.
Our R&D infrastructure includes a comprehensive suite of advanced instruments, such as ICP-MS, LC-MS, GC-MS, ICP-OES, HPLC, GC, particle size analyzers, dissolution testers, and polarimeters.Together, these capabilities provide strong technical support for the precise investigation of every molecule and every critical quality attribute..
All of these investments and accumulated capabilities have ultimately crystallized into industry-leading R&D platforms and system-level competencies. In addition to national-level R&D entities such as a National Enterprise Technology Center and a National Postdoctoral Research Workstation, we have been approved to establish the Shandong Provincial Key Laboratory for Radionuclide Drug Conjugates R&D and the Shandong Provincial Engineering Research Center for Radionuclide Drug Conjugates, providing systematic support for innovation at its source.
